Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:INDV TSE:ITH NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$10.87-2.7%$13.48$10.71▼$19.50$1.95B0.2654,242 shs120,950 shsINDVIndivior$37.62+0.5%$34.61$13.42▼$41.00$4.57B0.881.77 million shs1.59 million shsITHInternational Tower Hill MinesC$2.84-18.4%C$3.41C$1.14▼C$4.94C$910.50M2.11740381,346 shs122,071 shsSOPHSOPHiA GENETICS$5.00+0.8%$4.94$2.59▼$5.70$339.69M0.9888,959 shs79,685 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED-1.24%-0.53%-16.02%-19.35%-26.99%INDVIndivior+5.53%+2.13%-5.56%+15.86%+173.51%ITHInternational Tower Hill Mines+2.35%-1.69%+12.62%-15.53%+161.65%SOPHSOPHiA GENETICS+3.77%-2.36%-2.17%+14.02%+65.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$10.87-2.7%$13.48$10.71▼$19.50$1.95B0.2654,242 shs120,950 shsINDVIndivior$37.62+0.5%$34.61$13.42▼$41.00$4.57B0.881.77 million shs1.59 million shsITHInternational Tower Hill MinesC$2.84-18.4%C$3.41C$1.14▼C$4.94C$910.50M2.11740381,346 shs122,071 shsSOPHSOPHiA GENETICS$5.00+0.8%$4.94$2.59▼$5.70$339.69M0.9888,959 shs79,685 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED-1.24%-0.53%-16.02%-19.35%-26.99%INDVIndivior+5.53%+2.13%-5.56%+15.86%+173.51%ITHInternational Tower Hill Mines+2.35%-1.69%+12.62%-15.53%+161.65%SOPHSOPHiA GENETICS+3.77%-2.36%-2.17%+14.02%+65.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.40Hold$16.8054.55% UpsideINDVIndivior 3.00Buy$39.334.55% UpsideITHInternational Tower Hill Mines 0.00N/AN/AN/ASOPHSOPHiA GENETICS 2.33Hold$7.5050.00% UpsideCurrent Analyst Ratings BreakdownLatest INDV, SOPH, ITH, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/1/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/21/2026SOPHSOPHiA GENETICS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.003/17/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)3/16/2026INDVIndivior Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/10/2026HCMHUTCHMED Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $20.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$548.51M3.46$2.59 per share4.20$7.17 per share1.52INDVIndivior$1.24B3.70$2.89 per share13.03($0.78) per share-48.23ITHInternational Tower Hill MinesN/AN/AC$0.13 per share22.50C$0.69 per shareN/ASOPHSOPHiA GENETICS$77.27M4.43N/AN/A$0.69 per share7.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$456.91MN/AN/A18.74N/AN/AN/AN/A8/3/2026 (Estimated)INDVIndivior$210M$1.9519.298.81N/A19.44%-219.26%29.40%7/30/2026 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.01N/AN/AN/AN/A-2.04%-3.65%N/ASOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%8/4/2026 (Estimated)Latest INDV, SOPH, ITH, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ITHInternational Tower Hill MinesN/AC$0.01N/AC$0.01N/AN/A5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/11/2026Q4 2025ITHInternational Tower Hill MinesN/A-C$0.02N/AN/AN/AN/A3/6/2026H2 2025HCMHUTCHMED$2.50$0.0060-$2.4940N/A$290.50 million$135.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.054.964.83INDVIndiviorN/A0.860.66ITHInternational Tower Hill MinesN/A238.0330.48SOPHSOPHiA GENETICS1.052.061.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%INDVIndivior60.33%ITHInternational Tower Hill Mines8.85%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%INDVIndivior0.74%ITHInternational Tower Hill Mines0.51%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableITHInternational Tower Hill Mines220261.64 millionN/ANot OptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableHCM, ITH, SOPH, and INDV HeadlinesRecent News About These CompaniesSophia Genetics and MSK join forces to develop precision oncology hubJune 5 at 9:37 AM | yahoo.comSOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer CenterJune 4 at 8:00 AM | prnewswire.comSOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,750.00 in StockJune 1, 2026 | marketbeat.comSOPHiA GENETICS Files Form 6-K and Publishes 2025 ESG Impact SummaryMay 19, 2026 | tipranks.comSynnovis and SOPHiA GENETICS partner to bring blood-based cancer testing to patients across UKMay 15, 2026 | pharmabiz.comPSynnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.May 13, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), SOPHiA GENETICS (SOPH) and Solventum Corporation (SOLV)May 9, 2026 | theglobeandmail.comSOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG ResearchMay 6, 2026 | marketbeat.comSOPHiA Genetics (SOPH) Q1 2026 Earnings TranscriptMay 5, 2026 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comBTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8May 5, 2026 | finance.yahoo.comSOPHiA GENETICS Reports First Quarter 2026 ResultsMay 5, 2026 | prnewswire.comUncovering MTAP deletions in precision oncology researchApril 30, 2026 | labroots.comLHow The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value TargetsApril 26, 2026 | finance.yahoo.comSOPHiA GENETICS SAApril 23, 2026 | edition.cnn.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026April 21, 2026 | prnewswire.comMount Sinai adopts AI platform to advance genomic testingApril 18, 2026 | beckershospitalreview.comBSOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken Sells 2,800 SharesApril 17, 2026 | insidertrades.comMount Sinai uses AI to enhance the speed of genomic testingApril 16, 2026 | healthcareitnews.comHMount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026April 16, 2026 | prnewswire.comWell Daan Van Sells 2,400 Shares of SOPHiA GENETICS (NASDAQ:SOPH) StockApril 15, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong MomentumBy Chris Markoch | May 10, 20263 Stocks to Own If Gas Prices Keep RisingBy Dan Schmidt | May 16, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 2026HCM, ITH, SOPH, and INDV Company DescriptionsHUTCHMED NASDAQ:HCM$10.87 -0.30 (-2.69%) Closing price 04:00 PM EasternExtended Trading$10.86 -0.01 (-0.09%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Indivior NASDAQ:INDV$37.62 +0.17 (+0.45%) Closing price 04:00 PM EasternExtended Trading$37.90 +0.28 (+0.74%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.International Tower Hill Mines TSE:ITHC$2.84 -0.64 (-18.39%) As of 04:00 PM EasternInternational Tower Hill Mines Ltd. has a 100% interest in its Livengood Gold Project located along the paved Elliott Highway, 70 miles north of Fairbanks, Alaska.SOPHiA GENETICS NASDAQ:SOPH$5.00 +0.04 (+0.81%) Closing price 04:00 PM EasternExtended Trading$5.00 +0.00 (+0.02%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
